1.TESLA:-Should Elon Musk decide to unload some of his stake in Tesla  Inc, he will be capitalizing on a massive rally that has made the electric-vehicle maker one of the world’s most valuable companies.

The Tesla chief asked his Twitter  followers on Saturday if he should sell 10% of his Tesla stake. Nearly 58% said they would support such a sale, leading the stock to fall 4.9% when trading resumed on Monday.

Musk polled his Twitter followers after a jump in Tesla shares in recent weeks extended a strong, if volatile, run for the stock since it was added to the S&P 100 Index late last year.

Trading in Tesla has averaged $19 billion a day in the past three months, more than any other U.S. company, according to Refinitiv data.

Here is a closer look at Tesla’s shares:

After falling in the first half of 2021, Tesla shares have soared in recent weeks. Since Oct. 20, the stock has gained some 34%, with the S&P 500 up 3.6% over that time, a move that has pushed the electric-car maker’s market value over $1 trillion.

With those recent gains, Tesla shares have now surged 67% since the stock joined the S&P 500 in late December, versus a 27% gain for the benchmark index over that time

 2.ASTRAZENECA  :-AstraZeneca’s antibody cocktail against COVID-19 received its first nod for registration in Australia, the country’s medical regulatory body said on Tuesday.

The Therapeutic Goods Administration said it granted provisional determination to the Anglo-Swedish drugmaker last week for its antibody cocktail, EVUSHELD, the first protective shot other than vaccines against COVID-19.

The regulator said the provisional determination is the first step in the process, adding that it now expects AstraZeneca  to submit an application for provisional registration shortly.

The determination of the antibody-based therapy, which is already under real-time review in Europe and pending emergency approval in the United States, comes as Australia boosts its vaccination rates, recently launching booster shots, amid easing curbs.

3.HSBC:-HSBC Holdings Plc  is ahead of its hiring targets for its Chinese retail wealth management business and is exploring re-entering India’s private banking business, senior executives said, as part of its plan to make Asia and wealth key pillars of growth.

Under a strategy spearheaded by Group CEO Noel Quinn, HSBC is ploughing $3.5 billion into its wealth and personal banking business, in line with its ambition to become Asia’s top wealth manager by 2025.

“We are the leading international bank in China, so we want to squeeze that opportunity,” said CEO of Wealth and Personal Banking Nuno Matos, one of four top executives moving to Hong Kong from London this year as part of the bank’s regional pivot.

4.SOFT BANK :SoftBank Group Corp shares jumped 10% on Tuesday, the first trading session after the Japanese conglomerate said it would spend up to 1 trillion yen ($8.8 billion) buying back almost 15% of its shares.

The company announced the buyback, long speculated by the market, after it revealed its quarterly earnings crashed to a loss amid a decline in the share prices of its portfolio companies and a regulatory crackdown in China.

The move puts SoftBank’s shares on track for the biggest daily jump in 11 months.

The buyback is SoftBank’s second largest after a record 2.5 trillion yen buyback launched during the depths of the COVID-19 pandemic last year. Shares of the tech group quadrupled during that buyback, but have since fallen 40% from a peak in May.

“Our analysis of buyback history indicates that SBG stock performs (and outperforms indices or BABA) during buybacks,” wrote Jefferies analysts Atul Goyal in a note, referring to Alibaba , the group’s largest asset. SoftBank owns about a quarter of Alibaba’s shares.

5.BOEING  :The number of Boeing  Co employees seeking a vaccine exemption on religious or medical grounds has reached more than 11,000 – or nearly 9% of its U.S. workforce – a level many times higher than executives initially estimated, people familiar with the matter told Reuters.

The widespread reluctance has left executives scrambling for a strategy that keeps employees safe and complies with President Joe Biden’s vaccine mandate for federal contractors, but avoids an exodus of engineering and factory labor, the people said.

The standoff comes as the U.S. planemaker tries to muscle through industrial and certification challenges on its 787, 777X and Starliner spacecraft programs, as well as depressed demand and supply-chain shortages.

Late last week, the White House pushed back to Jan. 4 its deadline for employees at federal contractors to be vaccinated or be tested regularly if they receive exemptions.

Boeing on Friday then delayed its deadline by about a month to Jan. 4 for employees to take a COVID-19 vaccine, or file an exemption on religious or medical grounds, according to industry sources and a company email seen by Reuters.